On Tuesday, the Centers for Medicare & Medicaid Services (CMS) granted Advanced Diagnostic Laboratory Test (ADLT) status to Guardant Health, Inc.'s GH Shield blood test, which is used for screening colorectal cancer (CRC).
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a top company in precision oncology, has released findings from its second annual survey called “Closing the Gap: CRC Screening Insights.” The survey revealed that 90% of the doctors questioned are worried about the number of patients who skip colorectal cancer (CRC) screenings, often because of fear and anxiety. However, the availability of a blood test could help improve screening rates.
We have just released a list of the 10 Best Performing Mid Cap Stocks to Buy, based on analyst recommendations. In this article, we will examine how Guardant Health, Inc. (NASDAQ:GH) compares to other top mid cap stocks suggested by analysts. On February 7, Simeon Hyman, a Global Investment Strategist at […]
The call began at 5:31 PM ET on January 1, 0000, for Guardant Health, Inc. (NASDAQ:GH) regarding their Q4 2024 earnings. Key participants included Zarak Khurshid, Helmy Eltoukhy, AmirAli Talasaz, and Mike Bell, along with various analysts from different firms. The operator welcomed everyone to the call and expressed gratitude for their attendance.
The main figures for Guardant Health (GH) provide an overview of the company's performance for the quarter that ended in December 2024. However, it could be useful to compare some important metrics with Wall Street predictions and the results from the same period last year.
Guardant Health (GH) reported a quarterly loss of $0.62 per share, which is worse than the Zacks Consensus Estimate of a $0.50 loss. This is an improvement compared to a loss of $1.58 per share from the same period last year.
On February 20, Guardant Health (GH -3.26%), a top company in precision oncology testing, shared its results for the fourth quarter. The total revenue increased by 30% compared to the previous year, reaching $201.8 million, which was higher than analysts' expectations of $192 million.
Guardant Health (GH) has the right mix of factors that could lead to a strong earnings report in the near future. Be ready for the important expectations.
Guardant Health (GH) has recently created a hammer chart pattern after a decline in value, suggesting that the stock has reached a support level. Additionally, there has been an increase in earnings estimate revisions, which may signal a potential change in the stock's trend soon.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a top company in precision oncology, has announced its participation in several upcoming investor conferences. They will hold one-on-one meetings at the BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT on February 11th and 12th. Additionally, they will take part in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston, MA on March 4th at 10:30 a.m. Eastern Time.